This clinical trial is focused on studying the treatment of Chronic Hepatitis B, a long-term infection of the liver caused by the hepatitis B virus. The study involves a new treatment approach using a medication called GSK3228836, which is an anti-sense oligonucleotide. This type of medication is designed to target and interfere with the virus’s genetic material, potentially reducing its ability to multiply. Following this, participants will receive a targeted immunotherapy called GSK3528869A, which aims to boost the body’s immune response against the virus. The study also includes patients who are already receiving a type of medication known as nucleos(t)ide analogue therapy, which helps to control the virus.

The purpose of the study is to evaluate the safety and effectiveness of this sequential treatment in patients with Chronic Hepatitis B who are stable on their current therapy. Participants will be randomly assigned to receive either the new treatment or a placebo. The study will monitor how well the treatment works in reducing the virus and improving the immune response, as well as any side effects that may occur. The treatment will be administered through injections, with GSK3228836 given subcutaneously (under the skin) and GSK3528869A given intramuscularly (into the muscle).

Throughout the study, participants will have regular check-ups to assess their health and the treatment’s impact on the virus. The study aims to provide valuable information on whether this new treatment approach can offer a better way to manage Chronic Hepatitis B and improve patient outcomes. The trial is expected to continue until early 2026, allowing researchers to gather comprehensive data on the treatment’s long-term effects.